PRE CLINICAL RESEARCH

CLINICAL RESEARCH

Study 1:

Product BioKesum™
CRO UKM, Malaysia
Study Design Randomized, Double- Blind, Placebo- controlled
Dosage 250mg per capsule: 2 capsule/day
No. of Subjects 40 (20 per arm)
Age group ≥ 35 and ≤59 years old
Supplementation duration 6 weeks
Primary Objective
  • To determine the efficacy of BioKesum™ on cognitive function of middle age adults by using validated cognitive assessments (CNSVS, WASI, RAVLT, CTMT, POMS, SF-36)
  • Safety bioprofile and Adverse Event Analysis
Results
  • Favourable mean changes observed in group  BioKesum™ compared to placebo for cognitive functions (graph 1) and psychosocial assessment (graph 2)
  • Groups experiencing good mood (POMS>15) showed significant intervention effect (p<0.05) for short term memory
  • Groups experiencing bad mood (POMS<15) showed significant intervention effect (p<0.05) in IQ and social functioning
  • Safe (no difference between and placebo).

Study 2:

Product BioKesum™  (ingredient in product called SuperUlam)
CRO Medicus, US
Study Design Randomized, Double- Blind, Placebo- controlled, arm- crossover
Dosage 150mg per capsule: 2 tablets before test (1 time supplementation)
No. of Subjects 20 subjects x 2 (crossover)= 40
Age group ≥ 35 and ≤65 years old
Study duration 7 days
Objectives
  •  To investigate improvements in attention through a battery of cognitive tests (CNSVS System) and mood changes (Profile Mood of States, POMS Questionnaires)
  • Adverse Event Analysis
Results
  • Neurostimulatory and neurocognitive performance enhancement effect impacting various aspects of cognition and memory at different times between 1 and 5 hours after a single dose
  • Safe (no difference between and placebo).

HIGH IN ANTIOXIDANT